State of knowledge of Cameroonian drug prescribers on pharmacovigilance

State of knowledge of Cameroonian drug prescribers on pharmacovigilance

Francis Nde^1,&, Aimé Bernard Djitafo Fah², Francis Ampère Simo³, Denis Wouessidjewe⁴

¹Acute Medicine, Medicine of Catastrophes, Public Health, Epidemiology, Biostatistics, Pharmaceutical Medicine, Faculty of Medicine and Pharmaceutical Sciences, at University of Douala, Douala, Cameroon ²UDM, Bangante, Cameroon, ³University of Yaounde I, UdM, Bangante, Cameroon, ⁴Joseph Fourier de Grenoble University, UFR de Pharmacology, Department Molecular Pharmacology, UMR 5063, Bât. E (André Rassat), Pôle chimie – BP53, 38041 Grenoble

^&Corresponding author
Francis Nde, Acute Medicine, Medicine of Catastrophes, Public Health, Epidemiology, Biostatistics, Pharmaceutical medicine, Faculty of Medicine and Pharmaceutical Sciences, at University of Douala, Douala, Cameroon

Durgs side effect has been widely studied through pharmacovigilance studies since the thalidomide problem [1]. Pharmacovigilance is widely spread and applied in European countries [2,3] and USA [4], and more and more in developing countries [5] where the health system makes a case of health professional training [6]. Drugs are widely used nowadays to fight diseases that threaten the lives and well- being of people in the world, particularly in Africa and hence the Cameroon. In this country, the drug represents a burden for patient as it could already be observed in a study since 1997 [7]. Though helpful, drugs have negative aspects, with possible reduction of patients of life of patients, hospital admissions and prolongation of hospital stays, and in extreme cases, may cause death. Although before a drug is put on the market it has to go through number of trials, there is no enough experience to watch all the possible side effects it may cause, especially in certain categories of populations like children and pregnant women, or in association with other drugs. Thus a need to follow up drugs side effect after it acceptance on the market, since the number of patients increases significantly and becomes practically unlimited. In this context, insignificant and undetectable in clinical trials adverse reactions may occur and should be seriously considered. However, besides monitoring the side effects of drugs like those developed by WHO through Cohort Event Monitoring, monitoring medication side effects is not sufficiently developed Sub-Saharan Africa [8]. Several pilot projects have been attempted in this part of Africa, showing in most of cases that pharmacovigilance is a major public health problem, and the need of improvement action to improve the situation [9]. Majority of these pilot projects are usually related to vertical programs malaria, ARV or vaccination types. In addition, they often reveal gaps in knowledge of the actors, in addition to a lack of infrastructure and communication device. Since the historical drama of Thalidomide, international scientific community immediately realized that despite clinical trials, with a good follow up, a drug remains dangerous after being placed on the market. Therefore, in order to avoid harm to patients and improve public health, it is essential to establish a well-organized system of pharmacovigilance. It also appears as an essential component of an effective drug regulation system, clinical practice and health programs. Despite the call from WHO to strengthen national pharmacovigilance systems, developing countries are still struggling to seriously include ir pharmacovigilance in their health information system. This goes through the assessment of health professional knowledge and practice of pharmacovigilance. Cameroon, this is not known, thus our motivation to carry out this study aiming to assess the health professional knowledge and practice of pharmacovigilance in this country.

From June to September 2013, we carried out a study on a sample drawn from a synthetized database of 12526 health professionals composed of physicians, pharmacists and dentists in registered as shown in the national health statistics report of Cameroon in 2010. We asserted that 10% of prescribers have no "knowledge" of pharmacovigilance. We therefore calculated a sample of 138 patients, with an error margin of 5% and a confident level of 95% using Epi Info statcalc. We extended our selection to the four groups as not only physicians prescribe drugs in Cameroon. We sent out to the sample population 200 questionnaires and received 149 exploitable responses. We analyzed data using IBM SPSS 20.0 software. We applied a 0.05 threshold for p-value for statistical significance when comparing proportions.

Our sample was composed of 55 % of males. We had 57 % of physicians, 23 % of pharmacists, 12 % of nurses and 8 % of dentists. Nearly all our respondents had already prescribed, as well as observed a side effect, which in half of cases was from a drug prescribed by them (Table 1). Of the reason the cases were not declared, not knowing to whom to declare was the first, followed by lack of adequate contact of where to declare (Table 2). Nearly all the declared cases were done through the drug representatives of pharmaceutical companies (Figure 1). Physicians and pharmacists gave the less wrong definition of pharmacovigilance than dentists and nurses. More of physicians and pharmacists also believed there was no functioning pharmacovigilance system in Cameroon (Table 3).

This study which is the first in Cameroon highlighted a certain number of important facts. Of the entire sample, only few had never heard about pharmacovigilance, despite nearly all of them have ever prescribed a drug or even observed side effects. It shows the interest to build on the level of awareness of health workers on the matter. Though, having about a tenth of the sample not being aware of it still also shows that the concept may not be well though in our faculties or once back home after training, our prescribers do not apply the concept in their practice. Such an observation was made in a study in Nigeria on a survey in prescribers [10]. It shows the interest of training continuously our prescribers on the topic. In this study, pharmacists appear to be the most informed about pharmacovigilance. This may be due to the fact that from their basic training, they are the most implicated in drug, and later on, in terms of contact, delivery, preparation and explaining to the patients. An important reason for non-declaring side effects was lack of adequate contact or information on where to declare. The entire sample believes it is important to declare side effects, but most of them declared to drug representatives from pharmaceutical companies. These representatives belong to companies with internal developed pharmacovigilance structures, required at national level through registration conditions. Building on such an operational scheme could be a possible channel to develop a good pharmacovigilance system while waiting for implementation of well-functioning one at national level. Half of the respondent in our study were not aware of an existing functional pharmacovigilance system in Cameroon; which is less than findings in a survey in a similar poor resource setting in 2013 [11]. Informing pharmaceutical companies' drug representatives rather than national system shows on one hand the willing to declare, but also the lack of strict regulation on procedures in reporting such events. The only few reported cases received at ministry of health levels come from vertical programs in general, as observed in vaccine program side effects follow-up [12]. Comparably to a study in Senegal in 2013 [13] most of the dentists in our country are not aware of such a system though they are potential important prescribers as shown in similar settings.

Pharmacovigilance is a public health problem in Cameroon and the problem due to lack of good knowledge and practice of prescribers precisely physicians, pharmacists, nurses, and dentists who are not always aware of an existing pharmacovigilance system in Cameroon.

Authors declare not competing interests.

All authors contributed actively to each part of the research. The author has read the final version of this manuscript.

Table 1: prescription behavior

Table 2: reason of non-declaration of side effects

Table 3: pharmacovigilance status of knowledge of prescribers

Figure 1: place of side effects cases declaration

1. Miller MT, Strömland K. Teratogen Update: Thalidomide: A Review, With a Focus on Ocular Findings and New Potential Uses. TERATOLOGY. 1999; 60(5):306?321. PubMed | Google Scholar


2. Garazzino S, Lutsar I, Bertaina C, Tovo PA, Sharland M. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better? Int J Antimicrob Agents. 2013; 42(2):99-118. PubMed | Google Scholar


3. Ferrajolo C, Verhamme KM, Trifirò G, 't Jong GW, Giaquinto C, Picelli G, Oteri A, de Bie S, Valkhoff VE, Schuemie MJ, Mazzaglia G, Cricelli C, Rossi F, Capuano A, Sturkenboom MC. Idiopathic acute liver injury in paediatric outpatients: incidence and signal detection in two European countries. Drug Saf. 2013; 36(10):1007-1016. PubMed | Google Scholar


4. Marcus KA, Sorbello A, Truffa M, Williams J, Raine JM, Powderly WG. Current advances in pharmacovigilance in the USA and Europe: meeting the challenges of safety monitoring in HIV. Curr Opin HIV AIDS. 2012; 7(4):292-298. PubMed | Google Scholar


5. Awodele O, Daniel A, Popoola TD, Salami EF. A study on pharmacovigilance of herbal medicines in Lagos West Senatorial District, Nigeria. Int J Risk Saf Med. 2013; 25(4):205-217. PubMed | Google Scholar


6. Osakwe A, Oreagba I, Adewunmi AJ, Adekoya A, Fajolu I. Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. Int J Risk Saf Med. 2013; 25(4):219-227. PubMed | Google Scholar


7. Blatt A, Chambon R, Lemardeley P. Legal format and costs of prescriptions at the Central Hospital in Yaounde, Cameroon. Med Trop. 1997; 57(1):37-40. PubMed | Google Scholar


8. Brasseur P Mt, Olliaro PL. Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal. Malar J. 2012; 11:402. PubMed | Google Scholar


9. Sevene E, Mariano A, Mehta U, Machai M, Dodoo A, Vilardell D, and al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Malar J. 2010; 12:335. PubMed | Google Scholar


10. Ohaju O, Iribhogbe O. Pharmacoepidemiology drug. Extends of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria. 2010; 19(2):191-195. PubMed | Google Scholar


11. Santosh K, Tragulpiankit P, Edwards I, Gorsanan S. Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal. Int J Risk Saf Med. 2013; 25(1):1-16. PubMed | Google Scholar


12. Breugelmans J, Lewis R, Agbenu E, Veit O, Jackson D, Domingo C, and al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Elsevier. 2013; (14):1819-1829. Google Scholar


13. Diouf M, Bodian S, Lo CM, Cisse D, Faye D, Touré B, Fall M. Sante Publique. [Pharmacovigilance among dentists: a survey of practitioners in Dakar, Senegal]. 2013; 25(1):69-76. PubMed | Google Scholar